Sprd 422 Mother And Son Trip Yuki Sakurai Avi C Anteprime Surgery Ra Upd May 2026

| Measure | Discharge (Day 3) | Post‑Trip (Day 17) | 3‑Month (Day 90) | Δ (Discharge→Post‑Trip) | p‑value | Effect Size | |---------|------------------|-------------------|------------------|------------------------|--------|-------------| | KOOS (total) | 42 ± 5 | 71 ± 4 | 78 ± 3 | +29 | < 0.001 | d = 1.8 | | KOOS‑Pain | 38 ± 6 | 69 ± 5 | 76 ± 4 | +31 | < 0.001 | d = 2.0 | | VAS (0‑10) | 7.2 ± 0.8 | 3.1 ± 0.5 | 2.4 ± 0.4 | –4.1 | < 0.001 | d = 1.9 | | SF‑36 PCS | 38 ± 3 | 52 ± 4 | 58 ± 3 | +14 | < 0.001 | d = 1.7 | | SF‑36 MCS | 45 ± 2 | 61 ± 3 | 66 ± 2 | +16 | < 0.001 | d = 2.1 | | AVI‑C Steps/day | 2 200 ± 300 | 7 500 ± 600 | 5 800 ± 400 | +5 300 | < 0.001 | d = 2.3 | | AVI‑C Stair climbs/day | 3 ± 1 | 18 ± 2 | 12 ± 1 | +15 | < 0.001 | d = 2.5 |

All improvements exceeded the established MCIDs for KOOS (10 points) and SF‑36 (5 points). | Measure | Discharge (Day 3) | Post‑Trip

The phrase “mother and son trip” is a descriptive tag indicating the setting of the video’s narrative — typically a vacation, road trip, or hot spring getaway where the two characters are placed in close quarters. In fictional drama, this setup is used to explore interpersonal tensions, emotional bonding, or conflicts. Without explicit context, the phrase itself is neutral: many mainstream films (e.g., The Way Way Back, Japanese Story) feature mother-son travel narratives. Without explicit context, the phrase itself is neutral:

In the case of SPRD-422, prior database listings (from non-explicit sources like JDrama or Asian movie trackers) have noted that the plot involves a son accompanying his mother on a rural trip, leading to dramatic or romantic misunderstandings — a common trope in certain genres of Asian melodrama and adult cinema alike. Without explicit context

Attempting to locate the exact file described by sprd 422 mother and son trip yuki sakurai avi c anteprime surgery ra upd poses several risks:

Both gave written informed consent; the study was approved by the Institutional Review Board (IRB 2024‑045).